Nichi-Iko Of Japan To Buy Major Stake In Aprogen Of S. Korea
This article was originally published in PharmAsia News
Executive Summary
Japan's Nichi-Iko Pharmaceutical is buying a third of South Korea's Aprogen to gain the start-up's bioengineered drugs to sell in the Japanese market
You may also be interested in...
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic Clears Up Confusion Over Validity Of GMP Certificates
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.
Need a specific report? 1000+ reports available
Buy Reports